At the forefront of modern toxicology, our New Approach Methodologies (NAM) leverage advanced in vitro models, computational tools, and multi-omics integration to provide predictive, human-relevant safety and efficacy assessments. NAMs enable reduced dependence on animal testing while accelerating product development with mechanistically rich data aligned to regulatory expectations.
Our NAM portfolio includes internationally validated OECD guideline methods:
We utilize dynamic microphysiological organ-on-chip models that replicate liver and cardiac tissue microenvironments under physiologically relevant conditions. These provide sensitive, early detection of DILI and cardiotoxic effects, enabling mechanistic toxicology and personalized risk assessment.
Harnessing artificial intelligence (AI) and machine learning (ML), we analyze complex toxicological datasets, integrating multi-omics data to map toxicant-induced biological perturbations onto established Adverse Outcome Pathways (AOPs). This approach enhances mechanistic understanding and predictive accuracy, guiding safer therapeutic development.
Cutting-edge, OECD-validated NAMs reducing animal use and increasing data relevancy.
Advanced organ-on-chip platforms modeling key human organ toxicities.
AI-driven, multi-omics integrated toxicology supporting regulatory decision-making.
Seamless project integration with expert bioinformatics and scientific consultation.
Proven track record delivering high-impact, regulatory-compliant NAM data.
